View in EDS

Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system.

Saved in:
Bibliographic Details
Title: Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system.
Authors: Reus, Philipp1,2 (AUTHOR), Guthmann, Hadar3,4 (AUTHOR), Uhlig, Nadja5 (AUTHOR), Agbaria, Majd3 (AUTHOR), Issmail, Leila5 (AUTHOR), Eberlein, Valentina5 (AUTHOR), Nordling-David, Mirjam M.3 (AUTHOR), Jbara-Agbaria, Doaa3 (AUTHOR), Ciesek, Sandra2,6 (AUTHOR), Bojkova, Denisa2 (AUTHOR), Cinatl, Jindrich2 (AUTHOR), Burger-Kentischer, Anke7 (AUTHOR), Rupp, Steffen7 (AUTHOR), Zaliani, Andrea1 (AUTHOR), Grunwald, Thomas5 (AUTHOR), Gribbon, Philip1 (AUTHOR), Kannt, Aimo1,6,8,9 (AUTHOR) aimo.kannt@itmp.fraunhofer.de, Golomb, Gershon3,4 (AUTHOR)
Source: Journal of Controlled Release. Dec2023, Vol. 364, p654-671. 18p.
Database: Academic Search Ultimate
Description
ISSN:01683659
DOI:10.1016/j.jconrel.2023.10.050